Amidst recent news on healthcare pricing, HTL-Strefa, part of the MTD Group, reinforces its commitment to delivering innovative, high-quality pen needles at lower costs, with the Droplet brand rapidly expanding across U.S. markets
WOODSTOCK, GA / ACCESSWIRE / October 4, 2024 / As you may have seen in recent news, there is growing pressure to make healthcare more affordable to patients. Core to our strategy at HTL-Strefa, an MTD company, is a relentless focus on reducing costs for the healthcare system while providing solutions that meet the top-notch quality standards.
HTL-Strefa, as part of the MTD Group, benefits from MTD’s global leadership in med tech, with vertically integrated manufacturing in Europe for a large part of its branded products related to the diabetes business (pen needles, safety pen needles, safety lancets, etc). This setup ensures upscale control over production processes, maintaining high quality while offering cost-efficient solutions. MTD Group is today the second-largest worldwide producer of pen needles and safety pen needles, with HTL-Strefa’s Droplet brand standing out as the fastest-growing pen needle brand in the U.S.* Our products are widely available at many retailers, including several national pharmacy chains. In addition to our focus on quality and cost, we are very focused on product innovation, such as Droplet Micron, the thinnest and shortest pen needle on the market.
To learn more about HTL Strefa and MTD Group and partnering with us to reduce the financial burden on healthcare systems, visit our site https://mydroplet.com/or contact us at info@htl-strefa.com
About MTD: https://mtdglobal.com/north-america
* IQVIA Manufacturer Volume Trend, Nov 22. Data on File
Contact Information
Patricia Gaillard
Director, Marketing
patricia.gaillard@htl-strefa.com
770-528-0410
SOURCE: HTL-Strefa
View the original press release on newswire.com.
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…